Journal article
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial
- Abstract:
- 10.1038/s43018-025-00967-
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 2.8MB, Terms of use)
-
- Publisher copy:
- 10.1038/s43018-026-01181-8
Authors
- Publisher:
- Nature Research
- Journal:
- Nature Cancer More from this journal
- Publication date:
- 2026-06-08
- DOI:
- EISSN:
-
2662-1347
- ISSN:
-
2662-1347
- Language:
-
English
- Keywords:
- Pubs id:
-
2433604
- Local pid:
-
pubs:2433604
- Source identifiers:
-
W7163881968
- Deposit date:
-
2026-06-16
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2026
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record